Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maksim L. Maksimov"'
Autor:
Ekaterina V. Kanner, Aleksandr V. Gorelov, Maksim L. Maksimov, Ilya D. Kanner, Nikita M. Lapkin
Publikováno v:
Медицинский совет, Vol 0, Iss 1, Pp 149-156 (2021)
The use of antibiotic drugs (ABDs) has significantly reduced the number of severe bacterial infectious diseases and mortality in children, especially in infants. But the widespread and unnecessary use of ABDs, including reserve antibiotics (the use o
Externí odkaz:
https://doaj.org/article/66979e461f514c30bf1cefe5b7fafa2c
Publikováno v:
Ожирение и метаболизм, Vol 16, Iss 4, Pp 31-36 (2019)
In the review article the authors discuss unsolved issues regarding vitamin and mineral support of patients undergoing bariatric/metabolic operations. Many patients refer for the surgery already having deficiencies of macro- and micronutrients and ne
Externí odkaz:
https://doaj.org/article/fac9f147cbdb4eb2810c9323e5ad75c5
Publikováno v:
Medical Journal of the Russian Federation. 28:89-98
This review aimed to analyze national and international literature on the safety of omalizumab in the treatment of moderate-to-severe bronchial asthma. Omalizumab is one of the longest-standing monoclonal antibodies and the first available treatment
Autor:
Victoria A. Dudareva, Anastasiya A. Shikaleva, Maksim L. Maksimov, Irina G. Dyadikova, Aleksey V. Shulaev
Publikováno v:
Kazan medical journal. 103:492-503
Childhood obesity is an acute problem in the European Region, including countries participating in the World Health Organization's European Childhood Obesity Surveillance Initiative. According to their data, the proportion of overweight children reac
Autor:
Natal'ja P Denisenko, George E. Barreto, Gjumrakch Aliev, Andrey A. Svistunov, Vladimir N. Chubarev, Vadim V. Tarasov, Maksim L. Maksimov, Ghulam Md Ashraf, Vitalij A Otdelenov, Dmitrij A Sychev
Publikováno v:
Drug Design, Development and Therapy
Cytochrome (CYP) 450 isoenzymes are the basic enzymes involved in Phase I biotransformation. The most important role in biotransformation belongs to CYP3A4, CYP2D6, CYP2C9, CYP2C19 and CYP1A2. Inhibition and induction of CYP isoenzymes caused by drug
Autor:
Marco Avila-Rodriguez, Maksim L. Maksimov, Vadim V. Tarasov, Andrey A. Svistunov, Vladimir N. Chubarev, Olga V. Dralova, George E. Barreto, Gjumrakch Aliev
Publikováno v:
Current Pharmaceutical Design. 22:895-903
Obesity and metabolic syndrome (MS) are risk factors for diabetes, cancer, some cardiovascular and musculoskeletal diseases. Pharmacotherapy should be used when the body mass index (BMI) exceeds 30 kg/m² or 27 kg/m² with comorbidity. Efficacy and s